Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 263

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 19
Chunk 263
---
,333                                       98.43  
  Balance, October 31, 2024 (**)                                                      4,429,547      $                                 1.57  
  Number                                                                              2,549,311                                              

  (*)       These warrants include a cashless exercise provision and repricing                                                                             
  (**)      See note 19(b) regarding the exercise of warrants.                                                                                             

As
of October 31, 2024, the following share purchase warrants were outstanding:

                                Exercise price per                  Exercise price per      Expiry date         
                                warrant shares                          warrant shares                          
                                                                                 (USD)                          
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      1,923          1,923      C$                      339.20                 $243.75      November 17, 2027   
    743,565        538,150      $                        1.077                  $1.077      April 5, 2028       
         75             75      C$                       1,800               $1,293.48      November 23, 2024   
  2,352,504        677,683      $                        1.077                  $1.077      September 17, 2028  
  1,331,480      1,331,480      $                         1.60                   $1.60      January 15, 2029    
  4,429,547      2,549,311                                                                                      

F-28

CLEARMIND
MEDICINE INC.

Notes to
the Consolidated Financial Statements

(Expressed
in United States Dollars)

  10.      Stock    

  On November 14, 2023, the shareholders of the Company approved the Omnibus Equity Incentive Plan, or the Omnibus Plan. Pursuant to the Omnibus Plan, the Company is authorized to grant options o...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

The
maximum number of common shares reserved for issuance in any 12 5 15 12 2

  The following table summarizes the changes in the Company’s stock options for the years ended October 31, 2024 and October 31, 2023:  
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────